1. Home
  2. XENE vs LMAT Comparison

XENE vs LMAT Comparison

Compare XENE & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XENE

Xenon Pharmaceuticals Inc.

HOLD

Current Price

$58.56

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$114.50

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XENE
LMAT
Founded
1996
1983
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.6B
IPO Year
2014
2006

Fundamental Metrics

Financial Performance
Metric
XENE
LMAT
Price
$58.56
$114.50
Analyst Decision
Strong Buy
Buy
Analyst Count
12
5
Target Price
$67.17
$105.80
AVG Volume (30 Days)
1.1M
206.5K
Earning Date
05-11-2026
04-30-2026
Dividend Yield
N/A
0.87%
EPS Growth
N/A
30.57
EPS
N/A
2.52
Revenue
$311,000.00
$249,602,000.00
Revenue This Year
N/A
$14.21
Revenue Next Year
$2,436.26
$8.88
P/E Ratio
N/A
$45.54
Revenue Growth
N/A
13.53
52 Week Low
$28.19
$78.01
52 Week High
$62.91
$115.33

Technical Indicators

Market Signals
Indicator
XENE
LMAT
Relative Strength Index (RSI) 65.00 65.79
Support Level $39.93 $81.60
Resistance Level $59.44 N/A
Average True Range (ATR) 1.86 3.15
MACD -0.17 0.02
Stochastic Oscillator 80.01 92.82

Price Performance

Historical Comparison
XENE
LMAT

About XENE Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

Share on Social Networks: